You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameScopolamine
Accession NumberDB00747  (APRD00616)
TypeSmall Molecule
GroupsApproved
DescriptionAn alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]
Structure
Thumb
Synonyms
(-)-hyoscine
(-)-scopolamine
(1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate
6,7-Epoxytropine tropate
alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Hyoscine
scopine (-)-tropate
scopine (−)-tropate
Scopolamine hydrobromide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Hydrobromide Injectionliquid0.4 mgintramuscular; intravenous; subcutaneousOmega Laboratories Ltd2008-05-31Not applicableCanada
Scopolamine Hydrobromide Injectionliquid0.6 mgintramuscular; intravenous; subcutaneousOmega Laboratories Ltd2008-07-08Not applicableCanada
Scopolamine Hydrobromide Injection 0.4mg/mlsolution.4 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Scopolamine Hydrobromide Injection 0.6mg/mlsolution.6 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Transderm Scoppatch, extended release1 mg/3dtransdermalNovatris Consumer Health, Inc.2007-10-02Not applicableUs
Transderm Scoppatch, extended release1 mg/3dtransdermalBaxter Healthcare Corporation2003-01-01Not applicableUs
Transderm Scoppatch, extended release1 mg/3dtransdermalPhysicians Total Care, Inc.2007-10-02Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Hydrobromideinjection, solution.4 mg/mLintramuscular; intravenous; subcutaneousAPP Pharmaceuticals, LLC2000-10-18Not applicableUs
International Brands
NameCompany
ScopodermNot Available
Transderm-ScopNovartis
Brand mixtures
NameLabellerIngredients
Atenolol ScopolamineTps
B-donnaWinder Laboratories, LLC
Belladonna Alkaloids With PhenobartbitalLiberty Pharmaceuticals, Inc.
Diban CapAyerst Laboratories
Donnagel LiqAyerst Laboratories
DonnatalKAISER FOUNDATION HOSPITALS
Donnatal ElixirAyerst Laboratories
Donnatal ExtentabsPBM Pharmaceuticals, Inc
Donnatal Extentabs SrtWyeth Ayerst Canada Inc.
Donnatal TabWyeth Ayerst Canada Inc.
Me-PB-hyosMethod Pharmaceuticals, Llc
PhenohytroWinder Laboratories, LLC
Propranolol ScopolamineTps
QuadrapaxRebel Distributors Corp
Re-PB Hyos ElixirKAISER FOUNDATION HOSPITALS
Se-donna Pb HyosSeton Pharmaceuticals
SaltsNot Available
Categories
UNIIDL48G20X8X
CAS number51-34-3
WeightAverage: 303.3529
Monoisotopic: 303.147058165
Chemical FormulaC17H21NO4
InChI KeyInChIKey=STECJAGHUSJQJN-FWXGHANASA-N
InChI
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[[email protected]]2C[C@@H](C[C@@H]1[[email protected]]1O[C@@H]21)OC(=O)[[email protected]](CO)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Beta-hydroxy acid
  • N-alkylpyrrolidine
  • Piperidine
  • Oxazinane
  • Morpholine
  • Hydroxy acid
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.
PharmacodynamicsScopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.
Mechanism of actionScopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
Related Articles
AbsorptionBioavailability is 10 - 50%
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationLess than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.
Half life4.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9615
Blood Brain Barrier+0.8218
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5174
P-glycoprotein inhibitor INon-inhibitor0.87
P-glycoprotein inhibitor IINon-inhibitor0.8623
Renal organic cation transporterInhibitor0.531
CYP450 2C9 substrateNon-substrate0.7002
CYP450 2D6 substrateNon-substrate0.7296
CYP450 3A4 substrateSubstrate0.5253
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.927
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9581
BiodegradationNot ready biodegradable0.9073
Rat acute toxicity2.0907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9378
hERG inhibition (predictor II)Non-inhibitor0.9167
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boca pharmacal inc
  • Private formulations inc
Packagers
Dosage forms
FormRouteStrength
Tabletbuccal; oral; sublingual; transmucosal
Capsuleoral
Liquidoral
Tabletoral
Tablet (extended-release)oral
Tablet, film coated, extended releaseoral
Elixiroral
Injection, solutionintramuscular; intravenous; subcutaneous.4 mg/mL
Liquidintramuscular; intravenous; subcutaneous0.4 mg
Liquidintramuscular; intravenous; subcutaneous0.6 mg
Solutionintramuscular; intravenous; subcutaneous.4 mg
Solutionintramuscular; intravenous; subcutaneous.6 mg
Patch, extended releasetransdermal1 mg/3d
Prices
Unit descriptionCostUnit
Oscion Cleanser 6% Lotion 340.2 gm Bottle88.56USD bottle
Oscion Cleanser 3% Lotion 340.2 gm Bottle85.69USD bottle
Isopto Hyoscine 0.25% Solution 5ml Bottle30.99USD bottle
Transderm-Scop 1.5 mg (1 Box Contains 4 Patches)14.87USD patch
Transderm-Scop 1.5 mg (1 Box Contains 10 Patches)12.04USD patch
Transderm-scop 1.5 mg/72hr12.01USD each
Scopolamine hbr crystals6.86USD g
Isopto hyoscine 0.25% drops5.59USD ml
Scopolamine 0.4 mg/ml vial5.4USD ml
Buscopan 20 mg/ml4.5USD ml
Pamine forte 5 mg tablet3.9USD tablet
Pamine 2.5 mg tablet2.66USD tablet
Methscopolamine Bromide 5 mg tablet2.17USD tablet
Methscopolamine brom 5 mg tablet2.09USD tablet
Methscopolamine Bromide 2.5 mg tablet1.67USD tablet
Methscopolamine brom 2.5 mg tablet1.61USD tablet
Scopace 0.4 mg tablet0.67USD tablet
Buscopan 10 mg Tablet0.34USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point59 °CPhysProp
water solubility1E+005 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.98SANGSTER (1994)
Caco2 permeability-4.93ADME Research, USCD
pKa7.75 (at 25 °C)SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility6.61 mg/mLALOGPS
logP1.4ALOGPS
logP0.89ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)6.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity79.72 m3·mol-1ChemAxon
Polarizability31.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yang Guodong, “Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent.” U.S. Patent US5543407, issued February, 1993.

US5543407
General References
  1. Putcha L, Cintron NM, Tsui J, Vanderploeg JM, Kramer WG: Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989 Jun;6(6):481-5. [PubMed:2762223 ]
External Links
ATC CodesA04AD01S01FA02N05CM05A04AD51
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (686 KB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Scopolamine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Scopolamine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Scopolamine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Scopolamine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Scopolamine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Scopolamine.
AclidiniumAclidinium may increase the anticholinergic activities of Scopolamine.
AclidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Scopolamine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Scopolamine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Scopolamine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Scopolamine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Scopolamine.
AlfentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Scopolamine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.
AmbenoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Scopolamine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Scopolamine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Scopolamine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.
AmoxapineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Scopolamine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Scopolamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Scopolamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Scopolamine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Scopolamine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Scopolamine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Scopolamine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Scopolamine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Scopolamine.
AzelastineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Scopolamine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Scopolamine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Scopolamine.
BenactyzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Scopolamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Scopolamine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Scopolamine.
BezitramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Scopolamine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Scopolamine.
Botulinum Toxin Type AScopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BScopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
BrimonidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Scopolamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Scopolamine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Scopolamine.
BuprenorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Scopolamine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Scopolamine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Scopolamine.
ButorphanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Scopolamine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Scopolamine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Scopolamine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Scopolamine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Scopolamine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Scopolamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Scopolamine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Scopolamine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Scopolamine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Scopolamine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Scopolamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Scopolamine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Scopolamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Scopolamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Scopolamine.
CimetropiumScopolamine may increase the anticholinergic activities of Cimetropium.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Scopolamine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Scopolamine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Scopolamine.
CitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Scopolamine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.
ClidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Scopolamine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Scopolamine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Scopolamine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Scopolamine.
ClomipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Scopolamine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Scopolamine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Scopolamine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Scopolamine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Scopolamine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Scopolamine.
CodeineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Scopolamine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Scopolamine.
CoumaphosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Coumaphos.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Scopolamine.
CyclizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.
CyclopentolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Scopolamine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Scopolamine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Scopolamine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Scopolamine.
DantroleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Scopolamine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Scopolamine.
DapoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Scopolamine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Scopolamine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Scopolamine.
DecamethoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Scopolamine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.
DesipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Scopolamine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.
DexetimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Scopolamine.
DextromoramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Scopolamine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Scopolamine.
DichlorvosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Scopolamine.
DifenoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Scopolamine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Scopolamine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Scopolamine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Scopolamine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Scopolamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Scopolamine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Scopolamine.
DonepezilThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Scopolamine.
DoxepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
DoxylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Scopolamine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
DronabinolScopolamine may increase the tachycardic activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Scopolamine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Scopolamine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Scopolamine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Scopolamine.
EchothiophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Scopolamine.
EdrophoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Scopolamine.
EluxadolineScopolamine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Scopolamine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Scopolamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Scopolamine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Scopolamine.
EscitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Scopolamine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Scopolamine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Scopolamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.
EthanolScopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Scopolamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Scopolamine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.
EthotoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Scopolamine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Scopolamine.
EthylmorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Scopolamine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Scopolamine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Scopolamine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Scopolamine.
EtoperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Scopolamine.
EtorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etorphine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Scopolamine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Scopolamine.
EzogabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Scopolamine.
FenfluramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Scopolamine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Scopolamine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Scopolamine.
FlibanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Scopolamine.
FlunarizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Scopolamine.
FluoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Scopolamine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Scopolamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Scopolamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Scopolamine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Scopolamine is combined with gabapentin enacarbil.
GalantamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Scopolamine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Scopolamine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Scopolamine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Scopolamine.
Ginkgo bilobaThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Scopolamine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Scopolamine.
GlycopyrroniumScopolamine may increase the anticholinergic activities of Glycopyrronium.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Scopolamine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Scopolamine.
GuanfacineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Scopolamine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Scopolamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Scopolamine.
HeroinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexamethonium.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Scopolamine.
HomatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.
HydrocodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Scopolamine.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.
HydromorphoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Scopolamine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Scopolamine.
IloperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Scopolamine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Scopolamine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Scopolamine.
IndalpineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Scopolamine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Scopolamine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Scopolamine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Scopolamine.
IsoflurophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Scopolamine.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Scopolamine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Scopolamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Scopolamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Scopolamine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Scopolamine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Scopolamine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Scopolamine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Scopolamine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Scopolamine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Scopolamine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Scopolamine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Scopolamine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Scopolamine.
LevocabastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Scopolamine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Scopolamine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Scopolamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Scopolamine.
LofentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Scopolamine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Scopolamine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.
Lu AA21004The risk or severity of adverse effects can be increased when Scopolamine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium Sulfate.
MalathionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Malathion.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Scopolamine.
MaprotilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Scopolamine.
MefloquineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Scopolamine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Scopolamine.
MemantineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Scopolamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Scopolamine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.
MethadoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Scopolamine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Scopolamine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Scopolamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Scopolamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Scopolamine.
MethsuximideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Scopolamine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine.
MetixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Scopolamine.
MetyrosineScopolamine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Scopolamine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Scopolamine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Scopolamine.
MilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.
MinaprineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
MirabegronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.
MirtazapineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Scopolamine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Scopolamine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Scopolamine.
MorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Scopolamine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with N-butylscopolammonium bromide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
NabiloneScopolamine may increase the tachycardic activities of Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Scopolamine.
NalbuphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Scopolamine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Scopolamine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Scopolamine.
NeostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Scopolamine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Scopolamine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Scopolamine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Scopolamine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Scopolamine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Scopolamine.
NormethadoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.
NVA237The risk or severity of adverse effects can be increased when Scopolamine is combined with NVA237.
OlanzapineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Scopolamine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Scopolamine.
OpiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Opium.
OrphenadrineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Scopolamine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Scopolamine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Scopolamine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Scopolamine.
OxybutyninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Scopolamine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Scopolamine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.
PancuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Scopolamine.
ParaldehydeScopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Scopolamine.
ParoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Scopolamine.
PentazocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.
PentoliniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentolinium.
PerampanelThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Scopolamine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.
PethidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pethidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Scopolamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Scopolamine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Scopolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Scopolamine.
PhysostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Scopolamine.
PipecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.
PipotiazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Scopolamine.
PizotifenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pizotifen.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Scopolamine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Scopolamine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Scopolamine.
Potassium ChlorideScopolamine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleScopolamine may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Scopolamine.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Scopolamine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Scopolamine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Scopolamine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Scopolamine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Scopolamine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Scopolamine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Scopolamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Scopolamine.
PrimidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Scopolamine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Scopolamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.
PromethazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Scopolamine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Scopolamine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Scopolamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Scopolamine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Scopolamine.
PyridostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Scopolamine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.
QuinidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Scopolamine.
RamelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.
RamosetronScopolamine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Scopolamine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Scopolamine.
RemifentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Scopolamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Scopolamine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Scopolamine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Scopolamine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Scopolamine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Scopolamine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Scopolamine.
RivastigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Scopolamine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Scopolamine.
RopiniroleScopolamine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine.
RotigotineScopolamine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Scopolamine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Scopolamine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Scopolamine butylbromide.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Scopolamine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Scopolamine.
SertralineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Scopolamine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Scopolamine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Scopolamine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Scopolamine.
SolifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Scopolamine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Scopolamine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Scopolamine.
StiripentolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Scopolamine.
SuvorexantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Suvorexant.
TacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Scopolamine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Scopolamine.
TapentadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Scopolamine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Scopolamine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Scopolamine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Scopolamine.
TetrabenazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Scopolamine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Scopolamine.
ThalidomideScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Scopolamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Scopolamine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Scopolamine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.
TiagabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Scopolamine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Scopolamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Scopolamine.
TiotropiumScopolamine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Scopolamine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.
TolterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Scopolamine.
TopiramateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Scopolamine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Scopolamine.
TramadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tramadol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Scopolamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Scopolamine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Scopolamine.
TrazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.
TrichlorfonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Scopolamine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.
TrimethaphanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.
TropicamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Scopolamine.
TubocurarineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Scopolamine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Scopolamine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Umeclidinium.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Scopolamine.
VecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Scopolamine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Scopolamine.
VigabatrinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Scopolamine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Scopolamine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Scopolamine.
VortioxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Scopolamine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.
ZiconotideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Scopolamine.
ZimelidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Scopolamine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Scopolamine.
ZonisamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Scopolamine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Scopolamine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Murasaki O, Kaibara M, Nagase Y, Mitarai S, Doi Y, Sumikawa K, Taniyama K: Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. J Pharmacol Exp Ther. 2003 Dec;307(3):995-1000. Epub 2003 Oct 8. [PubMed:14534362 ]
  2. Klinkenberg I, Blokland A: The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50. doi: 10.1016/j.neubiorev.2010.04.001. Epub 2010 Apr 14. [PubMed:20398692 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sucrose alpha-glucosidase activity
Specific Function:
Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.
Gene Name:
SI
Uniprot ID:
P14410
Molecular Weight:
209451.49 Da
References
  1. Minai-Tehrani D, Fooladi N, Minoui S, Sobhani-Damavandifar Z, Aavani T, Heydarzadeh S, Attar F, Ghaffari M, Nazem H: Structural changes and inhibition of sucrase after binding of scopolamine. Eur J Pharmacol. 2010 Jun 10;635(1-3):23-6. doi: 10.1016/j.ejphar.2010.02.040. Epub 2010 Mar 15. [PubMed:20230815 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, Rollema H: The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol. 2005 Jan 4;506(3):209-19. Epub 2004 Dec 15. [PubMed:15627430 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23